WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE)-- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results